- Home
- BIIB vs CHD Comparison
BIIB vs CHD Comparison
Compare BIIB & CHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- CHD
- Stock Information
- Founded
- BIIB 1978
- CHD 1846
- Country
- BIIB United States
- CHD United States
- Employees
- BIIB N/A
- CHD N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- CHD Package Goods/Cosmetics
- Sector
- BIIB Health Care
- CHD Consumer Discretionary
- Exchange
- BIIB Nasdaq
- CHD Nasdaq
- Market Cap
- BIIB 18.7B
- CHD 21.6B
- IPO Year
- BIIB 1991
- CHD N/A
- Fundamental
- Price
- BIIB $149.61
- CHD $81.80
- Analyst Decision
- BIIB Buy
- CHD Buy
- Analyst Count
- BIIB 25
- CHD 15
- Target Price
- BIIB $183.05
- CHD $103.40
- AVG Volume (30 Days)
- BIIB 1.6M
- CHD 2.0M
- Earning Date
- BIIB 10-30-2025
- CHD 10-31-2025
- Dividend Yield
- BIIB N/A
- CHD 1.44%
- EPS Growth
- BIIB N/A
- CHD N/A
- EPS
- BIIB 10.97
- CHD 2.12
- Revenue
- BIIB $10,065,900,000.00
- CHD $6,066,000,000.00
- Revenue This Year
- BIIB $2.03
- CHD $1.62
- Revenue Next Year
- BIIB N/A
- CHD $3.92
- P/E Ratio
- BIIB $13.64
- CHD $38.55
- Revenue Growth
- BIIB 4.77
- CHD 1.13
- 52 Week Low
- BIIB $110.04
- CHD $81.33
- 52 Week High
- BIIB $185.00
- CHD $116.46
- Technical
- Relative Strength Index (RSI)
- BIIB 57.12
- CHD 27.02
- Support Level
- BIIB $148.10
- CHD $87.10
- Resistance Level
- BIIB $151.91
- CHD $88.50
- Average True Range (ATR)
- BIIB 4.19
- CHD 1.54
- MACD
- BIIB -0.10
- CHD -0.46
- Stochastic Oscillator
- BIIB 70.62
- CHD 5.63
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About CHD Church & Dwight Company Inc.
Church & Dwight is the leading global producer of baking soda. Its portfolio extends beyond its legacy category to include laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its brands also include Batiste, OxiClean, Vitafusion, Hero, and TheraBreath, which together with Arm & Hammer constitute around 70% of its annual sales and profits. Most recently, the firm added Touchland and its hand sanitizer business to its fold. Even as it works to expand its product reach, Church & Dwight still derives around 80% of its sales from its home market in the US.